Category
All published pages assigned to the Peptide Profiles category.
ELABELA (ELA) is an endogenous peptide signal studied in development and cardiovascular biology. A 2026 study linked lower ELA levels to fetal congenital heart disease and proposed a mitochondria-related mechanism in cardiac progenitor cells.
Phosphorylated lantibiotics (pLANs) are a recently described class of RiPP (ribosomally synthesized and post-translationally modified peptide) antimicrobials. A 2026 NPJ Biofilms & Microbiomes paper linked pLAN-producing oral commensals (Streptococcus salivarius) to pathogen suppression in dysbiotic biofilms and reported an early human feasibility signal after short-term dosing.
HNP1 (human neutrophil peptide 1) is an alpha-defensin antimicrobial peptide produced by neutrophils and studied for membrane-active antibacterial effects and synergy with other innate peptides.
LL-37 (cathelicidin) is a human antimicrobial peptide involved in innate immune defense and widely studied for membrane-active antibacterial and immunomodulatory effects.
Vasoactive intestinal peptide (VIP) is an endogenous neuropeptide hormone involved in vasodilation, smooth muscle relaxation, and immune signaling. A 2026 preclinical paper reported VIP-induced autophagy and cytotoxicity in renal cell carcinoma models via a proposed SIRT3-dependent pathway.
Dermcidin is a human antimicrobial peptide found in sweat and other tissues. A 2026 study reported antiviral activity against influenza via binding hemagglutinin, with mouse protection data.
Liver-expressed antimicrobial peptide 2 (LEAP2) is an endogenous peptide that antagonizes ghrelin receptor signaling and has been studied in humans for acute effects on appetite and post-meal glucose.
A long-acting, synthetic dual agonist of the GLP-1 and GIP receptors, used clinically for type 2 diabetes and obesity.
A mitochondria-targeted aromatic peptide investigated in preclinical models of axonal injury and retinal ganglion cell neuroprotection.
A marine cyanobacterial cyclic peptide natural product reported to disrupt actin dynamics and show potent in vitro antimalarial activity.
A cyclic peptide engineered from an antimicrobial peptide scaffold (YD) that showed preclinical anti-fibrotic activity by suppressing TGF-β/Smad and MAPK pathway signaling in experimental models.
A short pineal peptide (often spelled epithalon) studied in aging biology and telomere/telomerase-related experiments; widely discussed online with claims that exceed the strongest human evidence.
A short peptide (often discussed as an EDR peptide family) that appears in gerontology and neurobiology literature; widely marketed online for sleep and brain benefits with limited modern clinical evidence.
A synthetic form of gonadotropin-releasing hormone (GnRH), an upstream hypothalamic signal in the reproductive hormone axis.
A family of neuropeptides (KISS1-derived) that strongly stimulate the reproductive hormone axis upstream of GnRH, studied in reproductive physiology and clinical fertility contexts.
A 12-amino-acid midkine-derived peptide (KARYNAQCQETI) studied as a potential vital pulp therapy agent to promote reparative dentine formation.
A somatostatin receptor targeting peptide (octreotate derivative) used as the targeting component in peptide receptor radionuclide therapy (PRRT), including 177Lu-DOTATATE for neuroendocrine tumors.
A GLP-2 analog peptide drug used in short bowel syndrome to improve intestinal absorption and reduce parenteral support needs in some patients.
An Annexin A1 (AnxA1)-derived N-terminal peptide used in inflammation-resolution research, with recent preclinical work in osteoarthritis models.
A novel antimicrobial peptide reported in 2026 to have activity against carbapenem-resistant Acinetobacter baumannii in vitro and in mouse infection models.
A VEGF-mimetic peptide studied in biomaterials work aiming to accelerate endothelialization of small-diameter vascular grafts.
An endogenous gut hormone peptide that signals through the GLP-1 receptor and forms the biological basis for GLP-1 receptor agonist drugs used in diabetes and obesity.
A disulfide-rich venom peptide from the Australian funnel-web spider that is being investigated for neuroprotection in ischemic stroke, with challenging manufacturing and folding requirements.
A research-stage recovery peptide discussed for soft tissue healing and gut protection.
A long-acting GHRH analog discussed for growth hormone signaling, recovery, and body composition.
A copper peptide used mostly in skincare, discussed for skin repair and remodeling.
A ghrelin-receptor growth hormone secretagogue discussed for sleep and recovery.
A mitochondrial-derived peptide discussed for metabolic resilience and exercise-adjacent effects.
A melanocortin peptide used for tanning, with significant safety and quality concerns.
A neuroactive peptide discussed for anxiety and calmer focus, with limited mainstream evidence.
An FDA-approved melanocortin drug for HSDD, discussed online as PT-141 for libido.
A neuroactive peptide discussed for cognition and neuroprotection, with most evidence preclinical.
A GHRH fragment peptide used in growth hormone stimulation contexts.
A marketplace label for thymosin beta-4 related recovery peptides, often discussed for tissue repair.
An FDA-approved GHRH analog used for HIV-associated lipodystrophy and visceral fat reduction.
An immune-modulating peptide (thymalfasin) studied across infectious and immune contexts.